Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,604.50
Bid: 1,604.00
Ask: 1,604.50
Change: -5.50 (-0.34%)
Spread: 0.50 (0.031%)
Open: 1,611.50
High: 1,615.50
Low: 1,599.50
Prev. Close: 1,610.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: FTSE 100 treads water as Fed takes centre-stage

Wed, 01st May 2024 11:55

(Alliance News) - London's FTSE 100 traded off session highs heading into Wednesday afternoon, as some pre-Federal Reserve decision nerves kicked in.

The FTSE 100 index slipped just 1.15 points to 8,142.98. The FTSE 250 was down 35.58 points, 0.2%, at 19,929.81, and the AIM All-Share was up 3.07 points, 0.4%, at 763.81.

The Cboe UK 100 was flat at 813.38, the Cboe UK 250 fell 0.2% to 17,252.36, and the Cboe Small Companies was up 0.1% at 15,743.17.

Financial markets in Paris and Frankfurt are closed on Wednesday.

The Fed announces its latest interest rate decision at 1900 BST. A press conference with Chair Jerome Powell follows half an hour later.

Scope Markets analyst Joshua Mahony commented: "Today sees the Federal Reserve step up to the plate once again, with Jerome Powell holding the markets in his hands. Recent concerns around a resurgence in inflation pressures have pushed back the expected rate cuts that had until recently been scheduled to commence next month. The market pricing for a June rate cut has shifted from 56% to just 6% in the past month, but even more incredibly we have seen it pushed all the way back to December, bypassing three meetings in the process.

"With the Fed's March dot plot having laid out plans to cut three times this year, it is evident that the recent inflationary surge has similarly taken Powell and his colleagues off-guard. Today is the opportunity for him to set new expectations, and there is understandable concern that this meeting will be dominated by a more hawkish tone. Given the dramatic shift in expectations by the markets, bulls will hope that Powell could provide a glimmer of hope that things may not be as bad as markets are portraying."

While the Fed is not slated to release another summary of economic projections, the press conference following the decision offers a chance for Chair Powell to offer some thoughts on the US interest rate outlook.

With a rate cut hat-trick for 2024 now a distant prospect, the dollar has been supported.

The pound was quoted at USD1.2485 early Wednesday, down from USD1.2523 at the time of the London equities close on Tuesday. The euro stood at USD1.0660, down from USD1.0690. Against the yen, the dollar was trading at JPY157.95, up from JPY157.44.

Pepperstone analyst Michael Brown said the "tide" could turn on the dollar soon, however.

"Although the USD has gained ground against all G10 peers since the turn of the year, signs are starting to emerge that the tide may well be turning against the greenback, as Fed pricing reaches 'max hawk', growth appears to soften, and geopolitical risk seems to dissipate," Brown added.

Still to come on Wednesday is the latest US ADP jobs report at 1315 BST.

Equities in New York are called to open lower. The Dow Jones Industrial Average is called down 0.3%, the S&P 500 down 0.5% and the Nasdaq Composite 0.8% lower.

In London, Smith & Nephew shares rose 2.7%, the best large-cap performer. The medical devices maker said first-quarter revenue rose 2.2% on a reported basis to USD1.39 billion from USD1.36 billion.

"Revenue growth in the first quarter was driven by solid performance in our Orthopaedics and Sports Medicine & ENT businesses, partially offset by some anticipated softness in Advanced Wound Management," Chief Executive Officer Deepak Nath said.

"We are confident in our outlook and look forward to all three of our business units contributing as we deliver another year of strong revenue growth."

Smith & Nephew maintained annual guidance, expecting reporting revenue growth of 4.3% to 5.3%.

GSK added 1.9% as it raised annual guidance. Shingles drug, Shingrix, was one stand-out performer in its first-quarter, but the drugmaker reported momentum across all business areas.

The London-based pharmaceutical maker said revenue in the first-quarter of the year was up 5.9% to GBP7.36 billion from GBP6.95 billion a year prior.

Pretax profit, however, weakened 29% to GBP1.36 billion from GBP1.91 billion. GSK reported 'other' expenses worth GBP533 million, swinging from GBP297 million in gains a year prior and hurting its bottom line. Cost of sales rose 1.5% to GBP1.97 billion from GBP1.94 billion.

GSK now expects annual revenue to rise at the upper part of its 5% to 7% range, at constant currency.

It expects constant currency operating profit growth in its core operations of 9% to 11%, its outlook raised from 7% to 10%. Core earnings per share growth of 8% to 10% at constant currency is now expected, the guidance bumped up from 6% to 9%.

Aston Martin shares went into reverse, losing 5.2%, sitting at the rear of the FTSE 250. The Gaydon, England-based carmaker said revenue in the first-quarter fell 10% to GBP267.7 million from GBP295.9 million a year earlier. Its pretax loss widened 87% to GBP138.8 million from GBP74.2 million.

The company reported 945 vehicle sales, down 26% from 1,269.

AJ Bell analyst Russ Mould commented: "Luxury car manufacturer Aston Martin has been sent to the stock market equivalent of the scrapyard after struggling to kick into gear. The company has reported a doubling of losses in the first quarter and missed expectations across the board – including on volumes. Aston Martin has stopped production on some of its core models ahead of the launch of a new range of vehicles which the company expects to power growth in the second half of this year and beyond, but there is little reason for investors to place any faith in this strategy.

"The company's valuation is a fraction of what it was when it listed back in 2018, rendering initial comparisons with Ferrari as ridiculous as setting a park jogger up against an Olympic middle-distance runner. Despite a recent refinancing, Aston Martin is still burdened with a hefty debt pile and it's likely in the last chance saloon at this point. If the new launches don't go well it's hard to see what road the business can take next."

On AIM, there was some M&A impetus for Trinity Exploration and Alpha Financial Markets Consulting shares.

Alpha Financial Markets Consulting rose 39% after it confirmed private equity interest. It has a market capitalisation of GBP531.5 million.

It said it has received a non-binding indicative proposal from Bridgepoint Advisers, and added that Cinven is also mulling an offer. The duo have until the close of play on May 29 to confirm whether they plan to make an offer for the specialist consultancy services provider.

Trinity Exploration surged 43%, while Touchstone Exploration fell 3.9%. Touchstone said it has struck an all-share deal to acquire Trinity.

The all-share agreement values the latter at GBP24.1 million. Touchstone Exploration, an oil and natural gas exploration and production active in Trinidad & Tobago, said the deal will create a "leading Trinidadian operator of scale".

It said: "The addition of Trinity's existing production portfolio, along with its exploration and development assets, will position the combined group as one of the leading independent operating companies dedicated to investing in both onshore and offshore activity to grow Trinidadian oil and gas production."

As part of the deal, Trinity shareholders will receive 1.5 new Touchstone shares for each Trinity share owned. Trinity shareholders will own just under 20% of the combined firm. Trinity directors consider the terms of the deal to be "fair and reasonable".

Brent oil was quoted at USD85.23 a barrel early on Wednesday afternoon London time, down from USD86.42 late Tuesday. Gold was quoted at USD2,291.09 an ounce, down from USD2,298.10.

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
3 Jun 2024 17:19

Pharma, energy stocks drag London's FTSE 100; ECB rate cut hopes cap losses

FTSE 100 down 0.2%, FTSE 250 up 0.8%

*

Read more
3 Jun 2024 17:00

LONDON MARKET CLOSE: FTSE 100 down amid shaky start in New York

(Alliance News) - The FTSE 100 in London closed lower on Monday, marking a mixed start to June, with GSK firmly at the bottom of the index.

Read more
3 Jun 2024 14:01

GSK immunotherapy bowel cancer drug works for 100% of patients

(Alliance News) - An immunotherapy drug could spare bowel cancer patients the need for surgery and chemotherapy after results showed it was effective in 100% of cases.

Read more
3 Jun 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 up, while Labour commits to defence

(Alliance News) - Stock prices in London were up at midday, after data from S&P Global signalled a return to growth for the UK manufacturing sector.

Read more
3 Jun 2024 09:08

TOP NEWS: GSK vows to appeal adverse Delaware court ruling on Zantac

(Alliance News) - GSK PLC on Monday said it will appeal a US court ruling that it should face jury trials relating to cases concerning the heartburn drug, Zantac.

Read more
3 Jun 2024 08:37

LONDON MARKET OPEN: Stocks up amid slew of manufacturing PMIs

(Alliance News) - Stock prices in London opened higher on Monday, ahead of local purchasing managers index data, and comparative prints from several other major global economies.

Read more
3 Jun 2024 08:00

LONDON BRIEFING: FTSE 100 seen up; GSK defends ranitidine cancer claim

(Alliance News) - Stocks in London are set to open higher on Monday, ahead of a data-heavy week, kicked off by a slew of manufacturing purchasing managers' index readings.

Read more
3 Jun 2024 07:30

GSK to appeal Delaware ruling on jury trials in Zantac cancer cases

(Sharecast News) - GSK shares were down almost 10% on Monday after a US court ruled that jury trials could hear expert witnesses in 70,000 cases brought by cancer sufferers claiming its Zantac heartburn drug caused their condition.

Read more
1 Jun 2024 21:35

Delaware judge lets more than 70,000 Zantac lawsuits go forward

June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.

Read more
1 Jun 2024 21:07

Delaware judge lets more than 70,000 Zantac lawsuits go forward

June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.

Read more
31 May 2024 17:45

US FDA approves Moderna's RSV vaccine with lower-than-expected efficacy in its label

May 31 (Reuters) - The U.S. Food and Drug Administration approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.

Read more
31 May 2024 16:01

US FDA approves Moderna's RSV vaccine, its second marketed product

May 31 (Reuters) - The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.

Read more
30 May 2024 20:56

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, May 30 (Reuters) - A third U.S. dairy worker tested positive for bird flu after exposure to infected cows, and was the first to suffer respiratory symptoms, U.S. officials said on Thursday in the latest expansion of the outbreak. Bird flu has been found in dairy cattle in nine states. This second case in a Michigan dairy worker was found through increased testing of people and cows in the state following the April 1 identification of a case in a Texas farm worker. Here's what you need to know about the outbreak.

WHY IS H5N1 OR BIRD FLU A CONCERN?

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.